Obesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook - MSN
MSNarrow_outwardObesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook By Reuters - Investing.com
Investing.comarrow_outwardShares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance - NBC Los Angeles
NBC Los Angelesarrow_outwardShares of Novo Nordisk plunge 15% after Wegovy-maker cuts full-year guidance
CNBCarrow_outwardObesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
Yahoo Financearrow_outwardObesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook
Reutersarrow_outwardObesity drugmaker Novo Nordisk cuts 2025 sales growth, operating profit outlook - MarketScreener
MarketScreenerarrow_outwardNovo Nordisk lowers sales and operating profit outlook for 2025 - uk.finance.yahoo.com
Uk.finance.yahoo.comarrow_outwardNovo Nordisk Partners with Chong Kun Dang for ‘Wegovy’ Boost - Businesskorea
Businesskoreaarrow_outwardClinical Trials Market Outlook 2025 to 2035: Key Players in Novo - openPR.com
OpenPR.comarrow_outwardNovo Nordisk Bets Big on India, creates new jobs - Business Today
Business Todayarrow_outwardNovo Nordisk Drops 3.77% As Technical Indicators Signal Bearish Momentum - AInvest
AInvestarrow_outwardWegovy Demand Grows As Novo Nordisk Faces Investor Doubts - Finimize
Finimizearrow_outwardNovo Nordisk Faces Possible Mass Tort Over Ozempic In NJ - Law360
Law360arrow_outwardCan Novo Nordisk keep its Wegovy winning streak alive? - Rolling Out
Rolling Outarrow_outwardKepler Capital Remains Bullish on Novo Nordisk A/S (NVO) - Insider Monkey
Insider Monkeyarrow_outwardNovo Nordisk drug receives recommendation from European expert panel - medwatch.com
Medwatch.comarrow_outwardViatris beats Novo in semaglutide patent feud, clearing hurdle for potential Wegovy generic - Fierce Pharma
Fierce Pharmaarrow_outwardThis Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk. - Barron's
Barron'sarrow_outwardNovo Nordisk to discontinue three insulin products; Thermo Fisher CFO to retire - Endpoints News
Endpoints Newsarrow_outwardNovo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.
24/7 Wall St.arrow_outwardNovo Nordisk Has So Much Room To Go (NYSE:NVO) - Seeking Alpha
Seeking Alphaarrow_outwardNovo Nordisk Owner Buys Microsoft Quantum Computer With Denmark - Bloomberg.com
Bloomberg.comarrow_outwardEIFO and the Novo Nordisk Foundation Acquire the World’s Most Powerful Quantum Computer - Novo Nordisk Fonden
Novo Nordisk Fondenarrow_outwardIOM and Novo Nordisk Foundation Bring AI-Powered Health Screenings to Underserved Communities - International Organization for Migration
International Organization for Migrationarrow_outwardMaximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnership - pharmaphorum
Pharmaphorumarrow_outwardNovo Nordisk shares gain after competitor pulls out of China, 27 Jun 2025 10:47 - Shares Magazine
Shares Magazinearrow_outward‘Very obvious:’ Novo Nordisk may be illegally advertising Ozempic, says Spain’s health secretary - Euronews.com
Euronews.comarrow_outwardNovo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety - PR Newswire
PR Newswirearrow_outwardNovo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game - statnews.com
Statnews.comarrow_outwardNovo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints - Investopedia
Investopediaarrow_outwardNew Novo Nordisk drug could beat market leaders for weight loss, early results show - Financial Times
Financial Timesarrow_outwardNovo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee - Fortune
Fortunearrow_outwardNovo Nordisk taps start-up for small-molecule weight-loss collaboration - C&EN
C&ENarrow_outwardNVIDIA Partners With Novo Nordisk and DCAI to Advance Drug Discovery - NVIDIA Newsroom
NVIDIA Newsroomarrow_outwardCan Novo Nordisk turn it around? - Investors' Chronicle
Investors' Chroniclearrow_outward3 Governance Lessons From Novo Nordisk’s Stunning CEO Dismissal - Forbes
Forbesarrow_outwardEPO meets with Novo Nordisk - epo.org
Epo.orgarrow_outwardNovo Nordisk: CEO to step down due to market challenges - Hargreaves Lansdown
Hargreaves Lansdownarrow_outwardWegovy-maker Novo Nordisk abruptly ousts chief executive - BBC
BBCarrow_outwardBoss of Ozempic-maker Novo Nordisk steps down - politico.eu
Politico.euarrow_outwardNovo Nordisk CEO steps down in tough weight loss market - Euractiv
Euractivarrow_outwardNovo Nordisk CEO to exit role - European Pharmaceutical Review
European Pharmaceutical Reviewarrow_outwardIn surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales - Al Jazeera
Al Jazeeraarrow_outwardEPO revokes another Novo Nordisk patent behind Ozempic and Wegovy drugs - JUVE Patent
JUVE Patentarrow_outwardNovo Nordisk: Is obesity wonder drug Wegovy losing its investment appeal? - Proactive Investors
Proactive Investorsarrow_outwardNovo Nordisk VP weighs in on Ozempic sales and future in Ireland - The Times
The Timesarrow_outwardWegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off - The Guardian
The Guardianarrow_outwardNovo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand - Pharmaceutical Technology
Pharmaceutical Technologyarrow_outward
Novo Nordisk close
- 2025-07-29 19:10 event
- 49 sourceslanguage
- 200+ ads_click
- 3 weeks ago schedule